The Trump ad­min­is­tra­tion is sig­nif­i­cant­ly build­ing the port­fo­lio of drugs avail­able through its di­rect-to-con­sumer plat­form TrumpRx, adding more than 600 gener­ic med­i­cines.

Pres­i­dent Don­ald Trump...

Af­ter suc­cess with the drug Win­re­vair, a band of en­tre­pre­neurs has found their next chal­lenge in a dif­fi­cult-to-treat lung dis­ease.

On Tues­day, Oor­ja Bio launched...

They say stick to what you know. And Paragon Ther­a­peu­tics knows how to do re­verse merg­ers.

The hub-and-spoke bi­o­log­ics com­pa­ny is mov­ing its mi­graine drug...

Bio­Marin’s en­zyme re­place­ment ther­a­py for a rare ge­net­ic dis­or­der called ENPP1 de­fi­cien­cy de­liv­ered mixed re­sults in a late-stage study.

Pa­tients with the con­di­tion don't pro­duce...

Nour­ish, a tele­health plat­form that arranges vir­tu­al ap­point­ments with nu­tri­tion­ists, just raised a new round that bumped its val­u­a­tion to $1.75 bil­lion, ac­cord­ing to a...

Just as Maziar Mike Doust­dar took the helm at No­vo Nordisk in the sum­mer of 2025, the com­pa­ny said it would re­or­ga­nizeits R&D ac­tiv­i­ties...